ResultsIQ

ResultsIQ › Latest results › Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited Q2 FY26 earnings call summary

NSE: SUNPHARMA · BSE: 524715

Earnings call of 5 Nov 2025, summarised by AI from the filing.

Sun Pharma Q2 FY26 sales rose 8.6% to ₹144,052 million and EBITDA 14.9% to ₹45,271 million, with U.S. innovative medicines surpassing generics.

Key takeaways

  1. R&D guidance Full-year R&D spend expected at lower end of the 6% to 8% guidance.
  2. U.S. mix shift U.S. Innovative Medicines sales surpassed generics for the first time in the quarter.
  3. Growth driver Global Innovative Medicines sales up 16.4% to $313 million, led by ILUMYA, CEQUA and ODOMZO.
  4. Main risk U.S. generics sales fell on additional competition and lower lenalidomide sales.

Original filing on BSE

Sun Pharmaceutical Industries Limited Q1 FY27 results

As filed: Revenue ₹15,300 cr (+10% year on year), EBITDA ₹4,418 cr (+3% year on year), PAT ₹2,901 cr (+27% year on year), EBITDA margin 28.9% (−219 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹14,612 cr (+13% year on year), EBITDA ₹3,954 cr (+6% year on year), PAT ₹2,710 cr (+26% year on year), EBITDA margin 27.1% (−161 bps). Score 41 of 100, In line with trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well below it. EBITDA margin fell 161 bps year on year. Consolidated profit +26% but standalone -70%. Revenue fell 6% from last quarter. Share price after the results: −0.9% in 30 days (Nifty 500: +1.0%).
  • Q3 FY26: Revenue ₹15,521 cr (+14% year on year), EBITDA ₹4,948 cr (+23% year on year), PAT ₹3,381 cr (+24% year on year), EBITDA margin 31.9% (+257 bps). Score 66 of 100, Above trend. Revenue and profit before exceptional items growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 257 bps year on year. Consolidated profit +16% but standalone -40%. Profit before exceptional items rose ₹925 cr on a year ago, more than the ₹722 cr it added the year before. Share price after the results: +9.9% in 30 days (Nifty 500: −1.1%).
  • Q2 FY26: Revenue ₹14,478 cr (+9% year on year), EBITDA ₹4,528 cr (+15% year on year), PAT ₹3,125 cr (+3% year on year), EBITDA margin 31.3% (+164 bps). Score 41 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin rose 164 bps year on year. Consolidated profit +3% but standalone -35%. Share price after the results: +6.2% in 30 days (Nifty 500: +2.8%).
  • Q1 FY26: Revenue ₹13,851 cr (+9% year on year), EBITDA ₹4,303 cr (+19% year on year), PAT ₹2,293 cr (+17% year on year), EBITDA margin 31.1% (+255 bps). Score 52 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was above it; profit before exceptional items growth was well below it. EBITDA margin rose 255 bps year on year. Consolidated profit -20% but standalone +217%. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Share price after the results: −8.0% in 29 days (Nifty 500: −2.5%).
  • Q4 FY25: Revenue ₹12,959 cr (+8% year on year), EBITDA ₹3,716 cr (+22% year on year), PAT ₹2,154 cr (+24% year on year), EBITDA margin 28.7% (+334 bps). Score 60 of 100, In line with trend. Revenue and profit before exceptional items growth were in line with the company's own trend; EBITDA growth was well above it. EBITDA margin rose 334 bps year on year. Consolidated profit -19% but standalone +130%. Revenue fell 5% from last quarter. Profit before exceptional items rose ₹698 cr on a year ago, more than the ₹507 cr it added the year before. Share price after the results: −3.1% in 29 days (Nifty 500: +2.0%).
  • Q3 FY25: Revenue ₹13,675 cr (+10% year on year), EBITDA ₹4,009 cr (+15% year on year), PAT ₹2,913 cr (+14% year on year), EBITDA margin 29.3% (+123 bps). Score 54 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin rose 123 bps year on year. Profit fell 4% from last quarter. Profit rose ₹352 cr on a year ago, against ₹380 cr the year before.
  • Q2 FY25: Revenue ₹13,291 cr (+9% year on year), EBITDA ₹3,939 cr (+24% year on year), PAT ₹3,037 cr (+27% year on year), EBITDA margin 29.6% (+356 bps). Score 60 of 100, In line with trend. EBITDA margin rose 356 bps year on year. Consolidated profit +27% but standalone -3%. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Sun Pharmaceutical Industries Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.